Abbott Laboratories Stock
€104.98
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Abbott
sharewise wants to provide you with the best news and tools for Abbott, so we directly link to the best financial data sources.
Financials
News
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Abbott Laboratories' (NYSE: ABT) October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock
This Top Dividend King Just Became an Even Better Buy
Abbott Laboratories (NYSE: ABT), a medical device specialist, has a lot going its way. The company has a large and diversified portfolio of products, which it routinely expands through new launches
Why Exact Sciences Stock Surged Today
Shares of Exact Sciences (NASDAQ: EXAS) climbed on Thursday after the medical diagnostics specialist agreed to be acquired by Abbott (NYSE: ABT) for $21 billion.
As of 2:30 p.m. EST, Exact
Why Exact Sciences Stock Blasted Nearly 24% Higher Today
News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24%
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.
And
Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Shows
CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (NYSE:ABT) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the
1 No-Brainer Dividend Stock to Buy and Hold Forever
There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of
Don't Overlook These 2 Dividend Kings in Today's Volatile Market
President Donald Trump's trade policies have introduced plenty of volatility to the stock market this year. Steeper tariffs could impact consumer spending and the broader economy in ways that could
GBTG Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.
Tuesday, Aug. 5, 2025 at 1:00 p.m. ET
Chief Executive Officer — Paul Abbott
Source Fool.com
Abbott Reports 10.5% EPS Growth for Fiscal Q2
Abbott Laboratories (NYSE:ABT), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that
Abbott (ABT) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.
Need a quote from one of our analysts? Email [email protected]
Abbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices